Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants

Journal of Clinical Pharmacology

Volumn 51, Issue 2, 2011, Pages 218-228

  Rebello, Sam ^a   Leon, Selene ^a   Hariry, Sam ^a   Dahlke, Marion ^a   Jarugula, Venkateswar ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

ABCB1 transporter; Aliskiren; direct renin inhibitor; P glycoprotein; verapamil

Indexed keywords

ALISKIREN; NORVERAPAMIL; PARACETAMOL; VERAPAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; SCROTAL PAIN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; FUMARATES; HUMANS; MALE; P-GLYCOPROTEIN; PROSPECTIVE STUDIES; VERAPAMIL; YOUNG ADULT;

EID: 79551698844     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010365717     Document Type: Article

References (23)

1. Wood JM, Maibaum J., Rahuel J., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003 ; 308: 698-705.
2. Tekturna (aliskiren hemifumarate) tablets [package insert]. Basel, Switzerland: Novartis ; 2008.
3. Rasilez (aliskiren hemifumarate) tablets [summary of product characteristics]. Basel, Switzerland: Novartis ; 2008.
4. Oh B-H., Mitchell J., Herron JR, Chung J., Khan M., Keefe D. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007 ; 49: 1157-1163.
5. Villamil A., Chrysant SG, Calhoun D., et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 ; 25: 217-226.
6. Kilo C., Taylor A., Tschoepe D., Ibram G., Fang H., Prescott MF Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007 ; 8: 190-198.
7. Azizi M., Menard J., Bissery A., Guyene T., Bura-Riviere A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol. 2007 ; 2: 947-955.
8. Vaidyanathan S., Jarugula V., Dieterich HA, Howard D., Dole WP Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008 ; 47: 515-531.
9. Vaidyanathan S., Camenisch G., Schuetz H., et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008 ; 48: 1323-1338.
10. Rebello S., Compain S., Feng A., Hariry S., Dietrich A., Jarugula V. Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects. Br J Clin Pharmacol. 2009 (submitted).
11. Isoptin-SR (verapamil hydrochloride) caplets [summary of product characteristics]. Ludwigshafen, Germany: Abbott GmbH ; 2003.
12. Yasui-Furukori N., Uno T., Sugawara K., Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005: 77: 17-23.
13. Lemma G., Wang Z., Hamman MA, Zaheer NA, Gorski JC, Hall SD The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther. 2006 ; 79: 218-230.
14. Inspra FDA Approval Package. Summary basis for approval of eplerenone (NDA 21-437). Clinical Pharmacology and Biopharmaceutics Review 021437/S-000 Part 01 (June 7, 2004 ).
15. Ranexa FDA Approval Package. Summary basis for approval of ranolazine (NDA 21-526). Clinical Pharmacology and Biopharmaceutics Review. http://www.fda.gov/cder/foi/nda/2006/21-526. Accessed October 19, 2008.
16. Belz GG, Doering W., Munkes R., Mathews J. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharm Ther. 1983 ; 33: 410-417.
17. Rodin SM, Johnson BF, Wilson J., Ritchie P., Johnson J. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharm Ther. 1998 ; 43: 668-672.
18. Drescher S., Glaeser H., Mürdter T., Hitzl M., Eichelbaum M., Fromm MF P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003 ; 73: 223-231.
19. Limoges D., Dieterich HA, Yeh CM, Vaidyanathan S., Howard D., Dole WP A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther. 2008 ; 46: 252-258. (Pubitemid 351663162)
20. Ayalasomayajula S., Yeh CM, Vaidyanathan S., et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol. 2008 ; 48: 799-811. (Pubitemid 351871965)
21. Azizi M., Webb R., Nussberger J., Hollenberg NK Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006 ; 24: 243-256.
22. Choi DH, Shin WG, Choi JS Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Eur J Clin Pharmacol. 2008 ; 64: 445-449.
23. Smith MS, Benyunes MC, Bjornsson TD, Shand DG, Pritchett EL Influence of cimetidine on verapamil kinetics and dynamics. Clin Pharmacol Ther. 1984 ; 36: 551-554.